

Corrigendum to: Renal Impairment, *C. difficile* Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials

Yoav Golan,¹ Herbert L. DuPont,^{2,3} Fernando Aldomiro,⁴ Erin H. Jensen,⁵ Mary E. Hanson,⁵ and Mary Beth Dorr⁵

¹Tufts Medical Center, Boston, Massachusetts, USA, ²University of Texas School of Public Health, Houston, Texas, USA, ³Baylor St. Luke's Medical Center, Houston, Texas, USA, ⁴Hospital Fernando Fonseca, EPE – Amadora/Sintra at Portugal, Area Metropolitana de Lisboa, Carnaxide, Portugal, and ⁵Merck & Co., Inc., Kenilworth, New Jersey, USA

Open Forum Infectious Diseases, Volume 7, Issue 7, July 2020, ofaa248, <https://doi.org/10.1093/ofid/ofaa248>

In “Renal Impairment, *C. difficile* Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis

of Pooled Data From 2 Randomized Clinical Trials”, *Open Forum Infectious Diseases*, Volume 7, Issue 7, July 2020, ofaa248, few errors occurred in Figure 1 and has been corrected.




Figure 1. Proportion of placebo-treated participants with rCDI in all participants subset by renal impairment status and in subgroups of participants with prespecified risk factors (Clinical Cure Population). Boxes above bars are differences and 95% confidence intervals. *Clinical Cure Population; †No history of CDI within previous 6 months; ‡History of CDI within previous 6 months; risk factors for rCDI: ≥65 years of age, immunocompromised, history of CDI in previous 6 months, severe CDI (Zar score ≥2), O27 strain.

Open Forum Infectious Diseases®2021

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. DOI: 10.1093/ofid/ofaa629